Elizabeth Peckham, DO
Neurology · Round Rock, TXNPI 1154533743
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by AbbVie at 32.0% of the total. Reporting peaked in 2020 at $6,695 and has fallen 65.9% since, to $2,285 in 2025.
Across 315 payments — averaging $48.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Amneal Pharmaceuticals LLC$2K
- Medtronic$2K
- Acorda Therapeutics, Inc$2K
- Sunovion Pharmaceuticals Inc.$1K
- Abbott$1K
- plus $2K from 28 others
Across 295 payments — averaging $19,127 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.4M
- Genentech, Inc.$959K
- AbbVie$788K
- Sage Therapeutics, LLC$536K
- Roche TCRC, Inc.$274K
- Sunovion Pharmaceuticals Inc.$254K
- plus $455K from 9 others
What the payments were for
- Consulting fees$5,63537%
- Speaking & faculty fees$3,25621%
- Travel & lodging$9776%
- Food & beverage$5,28535%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $4,845 |
| Amneal Pharmaceuticals LLC | 3 | $2,324 |
| Medtronic(2 entities) | 60 | $1,810 |
| Acorda Therapeutics, Inc | 7 | $1,547 |
| Sunovion Pharmaceuticals Inc. | 16 | $1,209 |
| Abbott | 70 | $1,060 |
| Novartis | 29 | $458 |
| Acadia Pharmaceuticals Inc | 25 | $383 |
| Sanofi | 9 | $199 |
| Amgen | 7 | $150 |
| Teva Pharmaceuticals USA, Inc. | 7 | $138 |
| GE HealthCare | 4 | $108 |
| MDD US Operations, LLC | 7 | $108 |
| Neurocrine Biosciences, Inc. | 5 | $90 |
| Greenwich Biosciences, Inc. | 2 | $83 |
| Lundbeck LLC | 3 | $83 |
| Pfizer | 5 | $81 |
| Biogen | 3 | $68 |
| Kyowa Kirin, Inc. | 3 | $66 |
| Eisai Inc. | 2 | $53 |
| Microtransponder, Inc. | 1 | $35 |
| Octapharma USA, Inc. | 2 | $34 |
| Avanir Pharmaceuticals, Inc. | 2 | $31 |
| Argenx US, Inc. | 1 | $24 |
| Merz North America, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $21 |
| UCB, Inc. | 1 | $20 |
| SK Life Science, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Life Molecular Imaging Ltd | 1 | $17 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,162 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 456 | $524,169 |
| NuplazidPimavanserin Tartrate | 53 | $315,081 |
| IngrezzaValbenazine Tosylate | 14 | $119,437 |
| GocovriAmantadine Hcl | 51 | $93,313 |
| Tetrabenazine | 12 | $64,505 |
| BotoxOnabotulinumtoxina | 49 | $63,525 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,408 | $58,955 |
| NourianzIstradefylline | 16 | $52,703 |
| NeuproRotigotine | 38 | $51,277 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 230 | $19,805 |
| Primidone | 293 | $9,707 |
| Rivastigmine | 30 | $9,205 |
| AmantadineAmantadine Hcl | 175 | $7,820 |
| Gabapentin | 359 | $7,007 |
| Pramipexole ErPramipexole Di-Hcl | 19 | $6,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $2,324 | $524,169456 claims |
| Acadia Pharmaceuticals IncNuplazid | $383 | $315,08153 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $90 | $119,43714 claims |
| MDD US Operations, LLCGocovri | $108 | $93,31351 claims |
| AbbVieBotox | $4,845 | $63,52549 claims |
| Kyowa Kirin, Inc.Nourianz | $66 | $52,70316 claims |
| UCB, Inc.Neupro | $20 | $51,27738 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.
Other neurology in Round Rock
- Ann BassSan Antonio$1.7M
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Benjamin GreenbergDallas$773K
- Annette OkaiPlano$730K
- Waleed El-FekyDallas$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.